Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, India.
aefis
chadox1 ncov-19 corona virus vaccine
healthcare workers
safety
severity
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
accepted:
31
01
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
12
3
2022
Statut:
epublish
Résumé
Background In January 2020, the Government of India based on the recommendation of the Drugs Controller General of India (DCGI) and National Technical Advisory Group on Immunization (NTAGI) started the rollout of the COVID-19 vaccine in the country. Two vaccines, ChAdOx1 nCoV-19 coronavirus vaccine (recombinant), i.e., COVISHIELD produced by Serum Institute of India and COVAXIN developed indigenously by Bharat Biotech, were given emergency use authorisation (EUA) by the DCGI. Methods In this cohort study, we assessed the incidence, pattern and severity of adverse events following immunization (AEFI) observed among the healthcare workers of a large tertiary care institute in eastern U.P., India vaccinated with ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant) within 30 minutes of vaccination by direct observation. Results Out of the total 836 healthcare workers who were vaccinated with the first dose of the vaccine, around 10% experienced any AEFI within the directly observed period. The most common AEFI was pain/tenderness at the injection site experienced by 59.3% of those who experienced any AEFI followed by headache/dizziness (35.3%), itching/rashes at the injection site (8.1%), nausea/vomiting (5.8%) and fever/chills (4.7%). The majority (95.3%) of the AEFIs observed were of minor severity with no serious AEFIs observed as per the WHO severity classification. Conclusion ChAdOx1 nCoV-19 Coronavirus vaccine (recombinant) is proven to be safe based on our findings as the majority of AEFIs observed were of minor grade only. However, the vaccine beneficiaries should be strictly observed for a minimum of 30 minutes at the vaccination site to look for any serious AEFI with arrangements to manage the same.
Identifiants
pubmed: 35273834
doi: 10.7759/cureus.21848
pmc: PMC8901079
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e21848Informations de copyright
Copyright © 2022, Kamble et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
MMWR Morb Mortal Wkly Rep. 2021 Jan 15;70(2):46-51
pubmed: 33444297
Lancet Infect Dis. 2021 May;21(5):637-646
pubmed: 33485468
Intern Emerg Med. 2021 Apr;16(3):803-804
pubmed: 33687691
NPJ Vaccines. 2021 Apr 21;6(1):60
pubmed: 33883557
Lancet. 2021 Jan 23;397(10271):264
pubmed: 33485435
Osong Public Health Res Perspect. 2021 Aug;12(4):203-214
pubmed: 34465070
J Korean Med Sci. 2021 Mar 08;36(9):e67
pubmed: 33686812
Infect Drug Resist. 2021 Oct 02;14:4077-4083
pubmed: 34629882
Travel Med Infect Dis. 2021 Mar-Apr;40:101989
pubmed: 33578045
Med J Armed Forces India. 2021 Jul;77:S505-S507
pubmed: 34334920
J Korean Med Sci. 2021 May 03;36(17):e114
pubmed: 33942578
J Korean Med Sci. 2021 Mar 15;36(10):e78
pubmed: 33724740